Amyotrophic lateral sclerosis (ALS) patients without any type of eye disease have thinner retinal layers, a new study shows. The research, titled “Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease” was published in the journal PLOS…
Being diagnosed with amyotrophic lateral sclerosis (ALS) is a difficult and stressful time. You’ll probably feel incredibly overwhelmed in the first few days and weeks, and struggle to understand the ramifications involved. To help with the process, we’ve compiled a list of tips for patients who have recently been diagnosed with…
Being diagnosed with amyotrophic lateral sclerosis (ALS) can be devastating for patients and their families and friends, but there are ways to move forward. We’ve put together a list of coping strategies to help you get through the first few weeks with help from the Mayo Clinic and alswindsor.ca. Allow time and space to…
Routinely measuring neurofilaments in the blood and spinal fluid of people with amyotrophic lateral sclerosis (ALS) can help identify patients with early symptoms, concludes a recent study. Researchers led by Dr. Emily Feneberg of England’s University of Oxford presented the study, “Multicenter evaluation of neurofilaments in early symptom onset amyotrophic…
The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…
Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…
This 2014 Roundabout U video is all about Todd Walker from Murray, Kentucky. Todd shares his ALS story, which began when he was suddenly unable to exercise like usual. At first, doctors thought Todd was suffering from depression as he had just lost his father but as his symptoms began…
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies targeting rare and serious diseases, providing marketing exclusivity for…
https://www.youtube.com/watch?v=FvC5KheFWG8 This video from Patients Like Me is all about Cris, who is a mother, grandmother, and great-grandmother. Cris also has amyotrophic lateral sclerosis (ALS). She was diagnosed two years ago but hasn’t had the time to sit around and get depressed about her diagnosis. In between spending time with…
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, the drug developer, announced in a press release. Orphan drug status aims to encourage therapies for rare and serious diseases through incentives such as seven years of market…
Get regular updates to your inbox.